Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RPA1 | P27694 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11867580 | 0.83 | RPA1 (0.43) | L3MBTL1GAARPA1MAPTALDH1A1 | |
| SCHEMBL10360347 | 0.81 | KMT2A (0.54) | L3MBTL1GAAMAPTALDH1A1 | |
| SCHEMBL238439 | 0.80 | GAA (0.46) | L3MBTL1GAARPA1MAPTALDH1A1 | |
| SCHEMBL10360358 | 0.79 | GAA (0.49) | GAAMAPTALDH1A1LMNA | |
| SCHEMBL11864144 | 0.75 | MAPT (0.47) | GAAMAPTALDH1A1LMNA | |
| SCHEMBL31522193 | 0.75 | ALDH1A1 (0.50) | L3MBTL1GAARPA1MAPTALDH1A1 | |
| SCHEMBL13902297 | 0.75 | ALDH1A1 (0.50) | L3MBTL1GAARPA1MAPTALDH1A1 | |
| SCHEMBL1895896 | 0.75 | L3MBTL1 (0.50) | L3MBTL1GAAALDH1A1SIGMAR1 | |
| SCHEMBL2526908 | 0.73 | GAA (0.40) | L3MBTL1GAARPA1MAPTALDH1A1 | |
| SCHEMBL236974 | 0.73 | KDM4A (0.45) | GAAALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097394-B1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2013-12-25 | — | — | EP | disclosed |
| US-8349878-B2 | 1,2,4-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-01-08 | — | — | US | disclosed |
| US-20120004211-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-8039497-B2 | 1,2,4-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-10-18 | — | — | US | disclosed |
| US-20100004224-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-01-07 | — | — | US | disclosed |
| EP-1921073-A1 | 1,2,4-Triazole derivatives as sigma receptor inhibitors | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004224-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRK1 | L3MBTL1 4856/4885GAA 2370/4885RPA1 2639/4885 |
| US-20120004211-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRK1 | L3MBTL1 4874/4885GAA 2286/4885RPA1 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.